prevalence varied from 0 in China and France to 4.8% in the US and to 11% in the Gulf Cooperation Council countries.
In 2017, we conducted a study on 300 potential kidney transplant recipients from 26 dialysis centers in Poland, representing 9.7% of all dialysis patients in these units [10] . We found that hepatitis B virus (HBV) and HCV taken together were more prevalent in patients on the inactive waiting list compared to those on the active list (3.0 vs. 1.5%, p < 0.05). We also looked at the prevalence of HBV and HCV, as well as that of anti-HBc antibodies, in patients from Fresenius Medical Care dialysis units (n = 5890, representing 1/3 of the whole hemodialysis population in Poland). We then compared the results with similar data from 2007 and with data from the transplantation waiting list in 2017 (Fig. 1) . On the waiting list, HBs+/HBV−DNA+ were found in 0.5%, HBs+/HBV−DNA− in 0.5%, anti-HCV−/HCV−RNA+ in 0.2%, and anti-HBc in 21.1% of the patients. In 2007, antiHBc was not tested. According to our results, the prevalence of HCV in Polish dialysis and waitlisted populations is comparable to that in the general population worldwide [5] and much lower than that in the US [9] . This could be due to the very strict infection control policy in our dialysis units, including the use of separate machines and rooms for HBV and HCV positive patients, as well for patients with anti-HBc antibodies. It also appears that, thanks to vaccination, the prevalence of HBV has declined. In our population, prevalence of HBV infection was similar to that of US [2] , Malaysia and Japan from Asian countries [3] , but much lower than in China, Thailand and Korea [3] .
With modern treatment of HCV using direct-acting antiviral (DAA) drugs, sustained viral response rate may reach 100% [11] . Thus, the cure of HCV in CKD stages 4-5, dialysis, and kidney transplant patients now seems possible, and the prevalence of HCV will likely decline rapidly in the near future. Moreover, the option of DAA treatment prior to transplantation has the advantages of shortened waiting times and expansion of the organ donor pool to include HCV+ donors [12] . However, there is a risk of DAA interaction with several other drugs, including calcineurin inhibitors [13] ; thus, the timing of antiviral therapy for waitlisted patients (before vs after transplantation) should be decided in collaboration with the transplant center.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of interest.
Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments. 
Informed consent

